Patent application number | Description | Published |
20080318887 | Antiproliferative activity of G-rich oligonucleotides and method of using same to bind to nucleolin - Compositions and methods for modulating tumor proliferation in an individual are provided. The methods employ nucleolin-binding agents, such as aptamers. The aptamers of the present invention can be used to modulate the proliferation of malignant, dysplastic, hyperproliferative, and/or metastatic cells through interference with molecular interactions and functions of nucleolin in the tumor cell. | 12-25-2008 |
20080318888 | Antiproliferative activity of g-rich oligonucleotides and method of using same to bind to nucleolin - Compositions and methods for modulating tumor proliferation in an individual are provided. The methods employ nucleolin-binding agents, such as aptamers. The aptamers of the present invention can be used to modulate the proliferation of malignant, dysplastic, hyperproliferative, and/or metastatic cells through interference with molecular interactions and functions of nucleolin in the tumor cell. | 12-25-2008 |
20080318889 | Antiproliferative activity of G-rich oligonucleotides and method of using same to bind to nucleolin - Compositions and methods for modulating tumor proliferation in an individual are provided. The methods employ nucleolin-binding agents, such as aptamers. The aptamers of the present invention can be used to modulate the proliferation of malignant, dysplastic, hyperproliferative, and/or metastatic cells through interference with molecular interactions and functions of nucleolin in the tumor cell. | 12-25-2008 |
20080318890 | Antiproliferative activity of G-rich oligonucleotides and method of using same to bind to nucleolin - Compositions and methods for modulating tumor proliferation in an individual are provided. The methods employ nucleolin-binding agents, such as aptamers. The aptamers of the present invention can be used to modulate the proliferation of malignant, dysplastic, hyperproliferative, and/or metastatic cells through interference with molecular interactions and functions of nucleolin in the tumor cell. | 12-25-2008 |
20090017009 | METHOD FOR THE DIAGNOSIS AND PROGNOSIS OF MALIGNANT DISEASES - Methods for the treatment of tumors and cancer by exploiting the surface expression of the usually nuclear-localized protein, nucleolin. | 01-15-2009 |
20090326047 | Antiproliferative activity of G-rich oligonucleotides and method of using same to bind to nucleolin - The present invention provides a method for inhibiting the proliferation of malignant and/or hyperplastic cells in a subject by administering to the subject a therapeutically effective amount of a guanosine rich oligonucleotide. The present invention also provides oligonucleotides which are capable of being specifically bound to a specific cellular protein which is nucleolin and/or nucleolin in nature, which is implicated in the proliferation of cells, specifically malignant and/or hyperplastic cells, and a method for their selection. | 12-31-2009 |
20110065121 | METHOD FOR THE DETECTION OF APOPTOSIS - Methods for the detection of apoptosis by measuring apoptotic bodies shed by apoptotic cells are provided, as are kits to carry out such methods. | 03-17-2011 |
20110178161 | Antiproliferative activity of G-rich oligonucleotides and method of using same to bind to nucleolin - Compositions and methods for modulating tumor proliferation in an individual are provided. The methods employ nucleolin-binding agents, such as aptamers. The aptamers of the present invention can be used to modulate the proliferation of malignant, dysplastic; hyperproliferative, and/or metastatic cells through interference with molecular interactions and functions of nucleolin in the tumor cell. | 07-21-2011 |
20120014942 | METHOD FOR THE DIAGNOSIS AND PROGNOSIS OF MALIGNANT DISEASES - Methods for the treatment of tumors and cancer by exploiting the surface expression of the usually nuclear-localized protein, nucleolin. | 01-19-2012 |
20120329866 | THERAPEUTIC COMPOUNDS - The invention provides compounds of Formula (I): | 12-27-2012 |
20130065227 | METHODS OF INCREASING MACROPINOCYTOSIS IN CANCER CELLS - This disclosure describes methods of stimulating macropinocytosis in cancer cells. | 03-14-2013 |
20140170076 | ANTI-NUCLEOLIN AGENT-CONJUGATED NANOPARTICLES - A composition comprises an anti-nucleolin agent conjugated to nanoparticles. The nanoparticles are non-magnetic, not iron oxide and not polyacrylamide. Furthermore, a pharmaceutical composition for treating cancer comprises a composition including an anti-nucleolin agent conjugated to nanoparticles, and a pharmaceutically acceptable carrier. | 06-19-2014 |
20140220013 | METHOD FOR THE DIAGNOSIS AND PROGNOSIS OF MALIGNANT DISEASES - Methods for the treatment of tumors and cancer by exploiting the surface expression of the usually nuclear-localized protein, nucleolin. | 08-07-2014 |
20140329911 | PREDICTIVE MARKER OF DNMT1 INHIBITOR THERAPEUTIC EFFICACY AND METHODS OF USING THE MARKER - Provided herein are methods for predicting efficacy of a DNA (cytosine-5)-methyltransferase 1 (DNMT1) inhibitor treatment in a subject having a cancer, methods of identifying a subject having a cancer that is more likely to respond to a DNMT1 inhibitor treatment, and methods of selecting a treatment for a subject having a cancer that include determining a level of SOX9 in a sample containing cells from a subject having a cancer. Also provided are methods of treating a subject having a cancer that include selectively administering a DNMT1 inhibitor to a subject having cancer determined to have an elevated level of SOX9 in a sample containing cells from the subject compared to a reference level. Also provided are antibodies and antigen-binding antibody fragments that specifically bind to SOX9, and nucleic acid sequences that contain at least 10 nucleotides complementary to a contiguous sequence present in a SOX9 nucleic acid for use in these methods. | 11-06-2014 |
20150025129 | COMPOUNDS, COMPOSITIONS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE - Certain embodiments of the invention include compositions comprising a compound of Formula (I), and salts, isomers, and derivatives thereof. Pharmaceutical compositions of some embodiments of the present invention comprise a compound of Formula (I), and salts, isomers, and derivatives thereof. Other embodiments of this invention include methods for treating disease (e.g., cancer) and methods for administering a compound of Formula (I), and salts, isomers, and derivatives thereof. | 01-22-2015 |